Practical recommendations for the use of Ryzodeg® 70/30 - Bundaberg
Practical recommendations for the use of Ryzodeg® 70/30 - Bundaberg
Applying the latest guidance to clinical cases
Agenda
Thursday, May 13
6:45 PM - 7:00 PM
6:45 PM - 7:00 PM
7:00 PM - 7:15 PM
7:00 PM - 7:15 PM
7:15 PM - 8:15 PM
7:15 PM - 8:15 PM
8:15 PM - 8:30 PM
8:15 PM - 8:30 PM
8:30 PM - 8:45 PM
8:30 PM - 8:45 PM
8:45 PM
8:45 PM
Meet the Speaker

Dr Tom Dover

Dr Tom Dover is an Endocrinologist and Obstetric Medicine Physician with degrees in Exercise Physiology and Dietetics & Clinical Nutrition (West Moreton Hospital & Health Service)

No records found.



Reference: 1.Ryzodeg® 70/30 (insulin degludec/insulin aspart) Approved Product Information October 2020.
Ryzodeg® 70/30 is a registered trademark of Novo Nordisk A/S. Novo Nordisk Pharmaceuticals Pty. Ltd. Level 3, 21 Solent Circuit, Baulkham Hills, NSW 2153. ABN 40 002 879 996.
NovoCare® Customer Care Centre (Australia) 1800 668 626. www.novonordisk.com.au. 

In accordance with the Code of Conduct for the prescription medicines industry in Australia, any costs (for example, travel or meals) incurred by a partner/spouse, guest or family member travelling with a healthcare professional must not be paid for or subsidised by the company.  Attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employer or professional association. If you do not wish to receive further invitations from Novo Nordisk or to receive a copy of our Privacy Policy please call 1800 668 626 or write to NovoCare® Customer Care Centre at Level 3, 21 Solent Circuit, Baulkham Hills NSW 2153. Novo Nordisk holds your information in accordance with the Privacy Act 1988, including for marketing purposes unless you tell us not to. You may ask to access your information. AU21RZG00001 January 2021